A Phase 2 interventional study of Saxagliptin and Saxagliptin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-04-03.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
To evaluate the positive efficacy trend among doses of saxagliptin (BMS-477118) in subjects with Type 2 diabetes mellitus by assessing the change from baseline in HbA1c following 12 weeks of double-blind treatment.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 423 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Saxagliptin
Drug: Saxagliptin
Drug: Saxagliptin
Drug: Saxagliptin
Drug: Saxagliptin
Drug: Saxagliptin
Drug: Placebo
Tablets, Oral, 2.5 mg, once daily, 12 weeks
Also known as: BMS-477118
Tablets, Oral, 5 mg, once daily, 12 weeks
Also known as: BMS-477118
Tablets, Oral, 10 mg, once daily, 12 weeks
Also known as: BMS-477118
Tablets, Oral, 20 mg, once daily, 12 weeks
Also known as: BMS-477118
Tablets, Oral, 40 mg, once daily, 12 weeks
Also known as: BMS-477118
Tablets, Oral, 100 mg, once daily, 6 weeks
Also known as: BMS-477118
Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
Analysis of Test for Positive Efficacy Trend in Change From Baseline in Hemoglobin A1c (A1C) at Week 12 in the 0-40 mg Cohort
Positive efficacy trend among doses of saxagliptin by assessing the adjusted mean change from baseline in A1C in the 0-40 mg cohort. The unit of measurement for A1C is percent.
Time frame: Baseline, Week 12
Change From Baseline in A1C at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in A1C at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in Fasting Serum Glucose (FSG) at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in FSG at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in Fructosamine at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in fructosamine achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in Fructosamine at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in fructosamine achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in Insulin at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in fasting insulin achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in Insulin at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in insulin achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in C-peptide at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in C-peptide achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in C-peptide at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in C-peptide achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in Postprandial Glucose 0-60 Minute Area Under the Curve (AUC) at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) glucose 0-60 minute AUC response to a liquid meal tolerance test (MTT) achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. Area Under the Curve (AUC) here is defined as the area under the plot of the serum concentration of glucose against time after ingesting the meal for the first 60 minutes after the subject drinks the liquid meal.
Time frame: Baseline, Week 6
Change From Baseline in Postprandial Glucose 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) glucose 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.
Time frame: Baseline, Week 12
Change From Baseline in Postprandial Insulin 0-60 Minute AUC at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) insulin 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.
Time frame: Baseline, Week 6
Change From Baseline in Postprandial Insulin 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) insulin 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.
Time frame: Baseline, Week 12
Change From Baseline in Postprandial C-peptide 0-60 Minute AUC at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.
Time frame: Baseline, Week 6
Change From Baseline in Postprandial C-peptide 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (postprandial) C-peptide 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.
Time frame: Baseline, Week 12
Change From Baseline in 15-minute Postprandial Glucose at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) glucose 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Postprandial Glucose at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial glucose 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 60-minute Postprandial Glucose at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) glucose 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 15-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) glucose 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial glucose 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 60-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) glucose 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 15-minute Postprandial Insulin at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial insulin 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Postprandial Insulin at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) insulin 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 60-minute Postprandial Insulin at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) insulin 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 15-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) insulin 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) insulin 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 60-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) insulin 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 15-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 60-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 15-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 60-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 15-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 60-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 15-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 60-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 15-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 60-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 15-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 60-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 15-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 60-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 15-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 60-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Postprandial Glucagon at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) glucagon 30 minutes after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Postprandial Glucagon at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) glucagon 30 minutes after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Postprandial Free Fatty Acids (FFA) at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) FFA 30 minutes after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Postprandial FFA at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) FFA 30 minutes after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Postprandial Glucagon Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) glucagon excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Postprandial Glucagon Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) glucagon excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Postprandial FFA Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Adjusted mean change from baseline in postprandial (after mealtime) FFA excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Postprandial FFA Excursion at Week 12 in the 0-40 mg Cohort
Adjusted mean change from baseline in postprandial (after mealtime) FFA excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.
Time frame: Baseline, Week 12
Change From Baseline in 15-minute Insulinogenic Index at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Mean change from baseline in 15-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.
Time frame: Baseline, Week 6
Change From Baseline in 15-minute Insulinogenic Index at Week 12 in the 0-40 mg Cohort
Mean change from baseline in 15-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.
Time frame: Baseline, Week 12
Change From Baseline in 30-minute Insulinogenic Index at Week 6 in the 0-40 and 0 & 100 mg Cohorts.
Mean change from baseline in 30-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.
Time frame: Baseline, Week 6
Change From Baseline in 30-minute Insulinogenic Index at Week 12 in the 0-40 mg Cohort
Mean change from baseline in 30-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.
Time frame: Baseline, Week 12
Change From Baseline in Matsuda Index at Week 6 in the 0-40 and 0 & 100 mg Cohorts
Mean change from baseline in Matsuda index achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. The Matsuda index is a scale designed to give numbers between 0 and 12, with a linear relationship to other indices of insulin sensitivity. The higher the number, the better the insulin sensitivity (improvement).
Time frame: Baseline, Week 6
Change From Baseline in Matsuda Index at Week 12 in the 0-40 mg Cohort
Mean change from baseline in Matsuda index achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The Matsuda index is a scale designed to give numbers between 0 and 12, with a linear relationship to other indices of insulin sensitivity. The higher the number, the better the insulin sensitivity (improvement).
Time frame: Baseline, Week 12
Change From Baseline in A1C at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts
Mean change from baseline in A1C achieved at each dose of saxagliptin during the Follow-Up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 \& 100 mg cohort.
Time frame: Baseline, Week 14
Change From Baseline in A1C at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts
Mean change from baseline in A1C achieved at each dose of saxagliptin during the Follow-Up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 \& 100 mg cohort.
Time frame: Baseline, Week 10, Week 16
Change From Baseline in FSG at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts
Mean change from baseline in FSG achieved at each dose of saxagliptin during Follow-Up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 \& 100 mg cohort.
Time frame: Baseline, Week 8, Week 14
Change From Baseline in FSG at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts
Mean change from baseline in FSG achieved at each dose of saxagliptin during the follow-up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 \& 100 mg cohort.
Time frame: Baseline, Week 10, Week 16
Change From Baseline in Fructosamine at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts
Mean change from baseline in fructosamine achieved at each dose of saxagliptin during the Follow-up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 \& 100 mg cohort.
Time frame: Baseline, Week 8, Week 14
Change From Baseline in Fructosamine at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts
Mean change from baseline in fructosamine achieved at each dose of saxagliptin during the Follow-up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 \& 100 mg cohort.
Time frame: Baseline, Week 10, Week 16
Change From Baseline in A1C at Week 6 by Baseline A1C Category in the 0 & 100 Cohort
Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin at Week 6 in subjects with baseline A1C \<7%, ≥7% to \<8%, ≥8% to \<9%, and ≥9% in the 0 \& 100 mg cohort.
Time frame: Baseline, Week 6
Change From Baseline in FSG at Week 6 in Subjects by Baseline FSG Category in the 0 & 100 mg Cohort.
Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin at Week 6 in subjects with baseline FSG \<140 mg/dL, ≥140 mg/dL to \<180 mg/dL, and ≥ 180 mg/dL in the 0 \& 100 mg cohort.
Time frame: Baseline, Week 6
Change From Baseline in 60 Minute Postprandial Glucose at Week 6 by Baseline Category in the 0 & 100 mg Cohort
Adjusted mean change from baseline in 60-minute postprandial glucose achieved at each dose of saxagliptin at Week 6 in subjects with baseline 60-minute postprandial glucose \<140 mg/dL, ≥140 to \<200 mg/dL, and ≥200 mg/dL in the 0 \& 100 mg cohort.
Time frame: Baseline, Week 6
Percentage of Participants Achieving A1C < 7% at Week 6 in the 0 & 100 mg Cohort
Percentage of participants achieving A1C \< 7%, the American Diabetic Association's defined goal for glycemia, at each dose of saxagliptin at Week 6 in the 0 \& 100 mg cohort.
Time frame: Week 6
Change From Baseline in 60-minute Postprandial FFA Excursion at Week 6 in the 0 & 100 mg Cohort
Adjusted mean change from baseline in postprandial FFA excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0 \& 100 mg cohort. (Note: this analysis was not performed.)
Time frame: Baseline, Week 6
Change From Baseline in 60-minute Postprandial Glucagon Excursion at Week 6 in the 0 & 100 mg Cohort
Adjusted mean change from baseline in postprandial glucagon excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0 \& 100 mg cohort. (Note: this analysis was not performed.)
Time frame: Baseline, Week 6
Discontinuations During the Double-Blind Phase Due to Lack of Glycemic Control
Number of participants discontinuing from the double-blind phase due to lack of glycemic control at Week 4 and Week 6. (Note: this analysis was not performed.)
Time frame: Week 4, Week 6
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Double-Blind Treatment Period in the 0-40 mg Cohort
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
Time frame: up to Week 12 for AEs; up to 30 days post-double-blind period but prior to follow-up period if any for SAEs and up to 30 days post-double-blind period for Discontinuations
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Double-Blind Treatment Period in the 0 & 100 mg Cohort
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
Time frame: up to Week 6 for AEs; up to 30 days post-double-blind period but prior to follow-up period if any for SAEs and up to 30 days post-double-blind period for Discontinuations
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0-40 mg Cohort
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
Time frame: From Week 12 to Week 16 for AEs; up to 30 days post follow-up in both cohorts for SAEs and Discontinuations
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0 & 100 mg Cohort
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
Time frame: From Week 6 to Week 10 for AEs; up to 30 days post follow-up in both cohorts for SAEs and Discontinuations
| Milestone | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) | Saxa 0-40 mg Cohort (Follow-up Period) | Saxa 0 & 100 mg Cohort (Follow-up Period) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 55 | 47 | 63 | 54 | 52 | 67 | 44 | 41 | 0 | 0 |
| Completed | 48 | 37 | 54 | 43 | 45 | 55 | 44 | 35 | 0 | 0 |
| Not completed | 7 | 10 | 9 | 11 | 7 | 12 | 0 | 6 | 0 | 0 |
| Withdrew: Administrative reason by sponsor | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 5 | 5 | 7 | 3 | 6 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Poor/noncompliance | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Subject no longer meets study criteria | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Subject withdrew consent | 4 | 3 | 3 | 1 | 1 | 2 | 0 | 3 | 0 | 0 |
| Milestone | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) | Saxa 0-40 mg Cohort (Follow-up Period) | Saxa 0 & 100 mg Cohort (Follow-up Period) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 309 | 80 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 296 | 78 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Poor/noncompliance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Subject withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
Positive efficacy trend among doses of saxagliptin by assessing the adjusted mean change from baseline in A1C in the 0-40 mg cohort. The unit of measurement for A1C is percent.
| percentage of glycosylated hemoglobins | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Analysis of Test for Positive Efficacy Trend in Change From Baseline in Hemoglobin A1c (A1C) at Week 12 in the 0-40 mg Cohort | -0.67 ± 0.80 | -0.95 ± 0.97 | -0.81 ± 0.91 | -0.74 ± 0.93 | -0.78 ± 1.04 | -0.29 ± 0.82 |
Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| percentage of glycosylated hemoglobins | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in A1C at Week 12 in the 0-40 mg Cohort | -0.72 ± 0.12 | -0.90 ± 0.14 | -0.81 ± 0.11 | -0.74 ± 0.12 | -0.80 ± 0.12 | -0.27 ± 0.11 |
Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| percentage of glycosylated hemoglobins | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in A1C at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -0.71 ± 0.09 | -0.72 ± 0.10 | -0.67 ± 0.09 | -0.68 ± 0.09 | -0.82 ± 0.09 | -0.33 ± 0.08 | -1.09 ± 0.09 | -0.36 ± 0.09 |
Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -10.71 ± 3.68 | -18.63 ± 3.82 | -16.10 ± 3.32 | -14.66 ± 3.57 | -18.34 ± 3.67 | -6.20 ± 3.26 | -26.33 ± 3.53 | -3.29 ± 3.81 |
Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in FSG at Week 12 in the 0-40 mg Cohort | -10.85 ± 4.61 | -21.68 ± 4.80 | -15.91 ± 4.16 | -13.61 ± 4.48 | -16.36 ± 4.60 | 2.81 ± 4.10 |
Adjusted mean change from baseline in fructosamine achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| umol/L | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Fructosamine at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -21.02 ± 3.91 | -21.87 ± 4.29 | -24.72 ± 3.65 | -23.96 ± 3.88 | -26.03 ± 4.07 | -9.26 ± 3.62 | -28.03 ± 3.74 | -0.16 ± 4.13 |
Adjusted mean change from baseline in fructosamine achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| umol/L | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in Fructosamine at Week 12 in the 0-40 mg Cohort | -20.89 ± 4.64 | -25.23 ± 5.14 | -21.31 ± 4.36 | -22.30 ± 4.64 | -26.30 ± 4.82 | -8.57 ± 4.33 |
Adjusted mean change from baseline in fasting insulin achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0, 100 mg Cohort) | Placebo (0, 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Insulin at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 1.88 ± 1.22 | 1.05 ± 1.26 | -0.99 ± 1.11 | -0.17 ± 1.18 | 0.38 ± 1.23 | 0.08 ± 1.11 | -2.03 ± 1.09 | -0.61 ± 1.13 |
Adjusted mean change from baseline in insulin achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in Insulin at Week 12 in the 0-40 mg Cohort | 2.38 ± 1.63 | 1.02 ± 1.93 | 1.41 ± 1.54 | 0.76 ± 1.74 | 2.29 ± 1.65 | 1.29 ± 1.51 |
Adjusted mean change from baseline in C-peptide achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in C-peptide at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -0.15 ± 0.12 | -0.19 ± 0.13 | -0.06 ± 0.11 | -0.02 ± 0.12 | -0.03 ± 0.13 | -0.08 ± 0.11 | -0.52 ± 0.12 | -0.13 ± 0.13 |
Adjusted mean change from baseline in C-peptide achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in C-peptide at Week 12 in the 0-40 mg Cohort | -0.04 ± 0.14 | -0.13 ± 0.16 | -0.09 ± 0.13 | 0.01 ± 0.14 | -0.02 ± 0.14 | 0.02 ± 0.13 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose 0-60 minute AUC response to a liquid meal tolerance test (MTT) achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. Area Under the Curve (AUC) here is defined as the area under the plot of the serum concentration of glucose against time after ingesting the meal for the first 60 minutes after the subject drinks the liquid meal.
| mg*min/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Postprandial Glucose 0-60 Minute Area Under the Curve (AUC) at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -1226 ± 318 | -1503 ± 353 | -1312 ± 290 | -1246 ± 320 | -1626 ± 324 | -461 ± 280 | -2035 ± 263 | -664 ± 283 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.
| mg*min/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in Postprandial Glucose 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort | -1121 ± 320 | -1505 ± 369 | -1730 ± 289 | -1377 ± 322 | -1520 ± 314 | 174 ± 275 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.
| uU*min/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Postprandial Insulin 0-60 Minute AUC at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 234.2 ± 149.5 | 293.2 ± 162.3 | 120.0 ± 136.6 | 165.4 ± 145.3 | 28.8 ± 152.4 | 164.6 ± 130.5 | -296.0 ± 160.4 | 261.9 ± 167.7 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.
| uU*min/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in Postprandial Insulin 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort | 61.2 ± 179.9 | 283.4 ± 218.0 | 114.2 ± 163.6 | 336.8 ± 177.7 | 195.6 ± 180.7 | 30.3 ± 155.6 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.
| ng*min/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Postprandial C-peptide 0-60 Minute AUC at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 0.2 ± 9.4 | 7.6 ± 10.3 | -5.5 ± 8.7 | 5.4 ± 9.2 | 0.2 ± 9.5 | -0.8 ± 8.3 | -19.7 ± 9.8 | 0.8 ± 10.1 |
Adjusted mean change from baseline in postprandial (postprandial) C-peptide 0-60 minute AUC response to a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort. Area Under the Curve (AUC) is defined as the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration. The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs.
| ng*min/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in Postprandial C-peptide 0-60 Minute AUC at Week 12 in the 0-40 mg Cohort | -8.1 ± 11.5 | 4.8 ± 14.0 | -1.6 ± 10.5 | 7.1 ± 11.4 | -3.4 ± 11.6 | -4.0 ± 10.0 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial Glucose at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -15.24 ± 5.22 | -16.53 ± 5.75 | -16.78 ± 4.72 | -14.35 ± 4.92 | -26.03 ± 5.38 | -9.30 ± 4.76 | -25.99 ± 4.30 | -6.80 ± 4.61 |
Adjusted mean change from baseline in postprandial glucose 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Glucose at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -23.45 ± 6.09 | -29.31 ± 6.80 | -25.32 ± 5.52 | -23.93 ± 5.74 | -30.60 ± 6.12 | -7.81 ± 5.57 | -36.33 ± 4.99 | -10.94 ± 5.42 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial Glucose at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -28.45 ± 6.85 | -39.99 ± 7.80 | -27.51 ± 6.21 | -24.32 ± 6.48 | -34.44 ± 6.90 | -4.96 ± 6.29 | -44.58 ± 5.65 | -17.22 ± 5.88 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort | -14.89 ± 4.78 | -16.45 ± 5.58 | -19.57 ± 4.35 | -18.70 ± 4.94 | -20.75 ± 4.77 | 0.77 ± 4.27 |
Adjusted mean change from baseline in postprandial glucose 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort | -19.79 ± 5.35 | -24.04 ± 6.21 | -28.59 ± 4.92 | -23.56 ± 5.52 | -20.42 ± 5.25 | -2.08 ± 4.76 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial Glucose at Week 12 in the 0-40 mg Cohort | -24.42 ± 6.73 | -35.30 ± 7.84 | -41.04 ± 6.14 | -27.54 ± 6.97 | -33.98 ± 6.71 | -1.41 ± 6.08 |
Adjusted mean change from baseline in postprandial insulin 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial Insulin at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 5.36 ± 2.74 | 2.22 ± 3.02 | 2.47 ± 2.53 | 3.11 ± 2.66 | -0.60 ± 2.77 | 0.60 ± 2.44 | -1.72 ± 3.07 | 1.63 ± 3.25 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Insulin at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 5.20 ± 3.39 | 8.51 ± 3.81 | 2.04 ± 3.18 | 1.10 ± 3.35 | -0.33 ± 3.40 | 4.82 ± 3.04 | -4.44 ± 3.30 | 7.69 ± 3.54 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial Insulin at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 2.35 ± 4.06 | 4.45 ± 4.49 | 0.25 ± 3.73 | 4.75 ± 3.93 | -0.13 ± 4.11 | 3.33 ± 3.59 | -8.17 ± 4.37 | 1.83 ± 4.56 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort | 2.93 ± 3.67 | 5.79 ± 4.49 | 2.87 ± 3.37 | 6.81 ± 3.74 | -1.48 ± 3.65 | 4.70 ± 3.17 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort | 0.98 ± 4.09 | 10.71 ± 5.01 | 2.48 ± 3.79 | 5.90 ± 4.16 | 6.14 ± 4.04 | 1.19 ± 3.54 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial Insulin at Week 12 in the 0-40 mg Cohort | 2.62 ± 4.36 | 4.61 ± 5.31 | 0.38 ± 3.95 | 4.99 ± 4.39 | 2.42 ± 4.40 | -2.22 ± 3.80 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 0.03 ± 0.17 | -0.09 ± 0.19 | -0.12 ± 0.16 | 0.17 ± 0.17 | -0.14 ± 0.17 | -0.13 ± 0.15 | -0.27 ± 0.17 | 0.01 ± 0.18 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 0.13 ± 0.20 | 0.16 ± 0.23 | -0.01 ± 0.19 | -0.06 ± 0.20 | -0.02 ± 0.21 | 0.03 ± 0.18 | -0.35 ± 0.21 | 0.05 ± 0.22 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial C-peptide at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -0.06 ± 0.22 | 0.36 ± 0.25 | -0.16 ± 0.21 | 0.20 ± 0.22 | 0.19 ± 0.22 | 0.24 ± 0.20 | -0.33 ± 0.25 | -0.10 ± 0.26 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 15 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort | -0.02 ± 0.23 | 0.11 ± 0.28 | -0.12 ± 0.21 | -0.02 ± 0.23 | -0.27 ± 0.23 | 0.07 ± 0.20 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 30 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort | -0.17 ± 0.23 | 0.27 ± 0.29 | 0.05 ± 0.22 | 0.19 ± 0.24 | 0.12 ± 0.23 | -0.14 ± 0.20 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide 60 minutes after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial C-peptide at Week 12 in the 0-40 mg Cohort | -0.08 ± 0.26 | 0.18 ± 0.31 | -0.02 ± 0.23 | 0.22 ± 0.26 | 0.01 ± 0.26 | 0.22 ± 0.23 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 1.42 ± 2.54 | -5.23 ± 2.82 | -1.15 ± 2.36 | 3.48 ± 2.64 | -0.95 ± 2.65 | -2.37 ± 2.30 | -1.12 ± 2.35 | 1.02 ± 2.52 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -7.39 ± 3.24 | -15.91 ± 3.64 | -6.92 ± 3.05 | -5.68 ± 3.34 | -6.89 ± 3.30 | -2.40 ± 2.92 | -12.76 ± 3.87 | -0.79 ± 4.22 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial Glucose Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -10.08 ± 4.01 | -23.94 ± 4.57 | -12.94 ± 3.75 | -6.10 ± 4.14 | -11.88 ± 4.09 | -1.31 ± 3.63 | -20.69 ± 4.09 | -8.59 ± 4.32 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort | -1.20 ± 2.68 | 0.02 ± 3.13 | 1.63 ± 2.47 | 3.14 ± 2.82 | -0.14 ± 2.68 | 1.89 ± 2.36 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort | -5.99 ± 3.26 | -5.24 ± 3.82 | -5.69 ± 3.06 | -0.73 ± 3.40 | -0.12 ± 3.22 | 0.79 ± 2.87 |
Adjusted mean change from baseline in postprandial (after mealtime) glucose excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial Glucose Excursion at Week 12 in the 0-40 mg Cohort | -9.29 ± 4.26 | -16.51 ± 5.01 | -19.44 ± 3.94 | -3.95 ± 4.43 | -13.83 ± 4.27 | 0.30 ± 3.79 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 5.58 ± 2.53 | -1.04 ± 2.75 | 2.85 ± 2.32 | 1.18 ± 2.47 | 0.11 ± 2.52 | -0.28 ± 2.24 | 2.19 ± 2.62 | 2.67 ± 2.78 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 4.95 ± 3.25 | 5.07 ± 3.61 | 2.40 ± 3.05 | -0.89 ± 3.24 | 0.13 ± 3.23 | 3.23 ± 2.91 | 0.22 ± 3.05 | 9.87 ± 3.27 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial Insulin Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 4.03 ± 3.93 | 1.84 ± 4.29 | 0.75 ± 3.60 | 2.28 ± 3.83 | -0.16 ± 3.93 | 1.82 ± 3.47 | -3.61 ± 3.78 | 4.19 ± 3.95 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort | 2.33 ± 3.08 | 5.26 ± 3.76 | 1.98 ± 2.85 | 3.56 ± 3.14 | -1.49 ± 3.05 | 4.42 ± 2.71 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort | -0.23 ± 3.47 | 10.17 ± 4.25 | 1.43 ± 3.25 | 3.35 ± 3.53 | 5.36 ± 3.44 | -0.70 ± 3.06 |
Adjusted mean change from baseline in postprandial (after mealtime) insulin excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| uU/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial Insulin Excursion at Week 12 in the 0-40 mg Cohort | 2.71 ± 3.97 | 4.85 ± 4.82 | -0.83 ± 3.63 | 2.02 ± 3.99 | 1.44 ± 4.01 | -3.52 ± 3.51 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 0.29 ± 0.14 | -0.08 ± 0.16 | 0.10 ± 0.13 | 0.08 ± 0.14 | 0.01 ± 0.14 | 0.01 ± 0.13 | 0.01 ± 0.15 | 0.17 ± 0.16 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 0.35 ± 0.18 | 0.11 ± 0.20 | 0.23 ± 0.17 | -0.07 ± 0.18 | 0.12 ± 0.18 | 0.09 ± 0.16 | -0.00 ± 0.20 | 0.31 ± 0.21 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial C-peptide Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 0.27 ± 0.20 | 0.35 ± 0.22 | 0.17 ± 0.19 | 0.12 ± 0.20 | 0.36 ± 0.20 | 0.17 ± 0.18 | 0.04 ± 0.21 | 0.20 ± 0.21 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (15 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort | 0.23 ± 0.16 | 0.42 ± 0.20 | 0.02 ± 0.15 | 0.02 ± 0.17 | -0.04 ± 0.16 | 0.21 ± 0.15 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort | 0.05 ± 0.20 | 0.58 ± 0.24 | 0.16 ± 0.18 | 0.28 ± 0.20 | 0.32 ± 0.19 | -0.08 ± 0.17 |
Adjusted mean change from baseline in postprandial (after mealtime) C-peptide excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin versus placebo at Week 12 in the 0-40 mg cohort.
| ng/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 60-minute Postprandial C-peptide Excursion at Week 12 in the 0-40 mg Cohort | 0.29 ± 0.22 | 0.59 ± 0.27 | 0.16 ± 0.20 | 0.27 ± 0.22 | 0.20 ± 0.22 | 0.13 ± 0.20 |
Adjusted mean change from baseline in postprandial (after mealtime) glucagon 30 minutes after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| pg/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Glucagon at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -11.84 ± 4.11 | -10.92 ± 4.93 | -11.26 ± 3.99 | -5.81 ± 4.56 | -9.04 ± 4.21 | -1.98 ± 3.82 | -14.97 ± 3.69 | 1.17 ± 3.75 |
Adjusted mean change from baseline in postprandial (after mealtime) glucagon 30 minutes after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.
| pg/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Glucagon at Week 12 in the 0-40 mg Cohort | -8.39 ± 4.12 | -6.06 ± 5.57 | -12.64 ± 4.30 | -17.21 ± 4.76 | -11.90 ± 4.41 | -3.64 ± 3.98 |
Adjusted mean change from baseline in postprandial (after mealtime) FFA 30 minutes after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| mEg/L | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Free Fatty Acids (FFA) at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 0.01 ± 0.03 | -0.03 ± 0.03 | -0.07 ± 0.02 | -0.08 ± 0.03 | -0.05 ± 0.03 | -0.02 ± 0.02 | -0.17 ± 0.02 | -0.16 ± 0.02 |
Adjusted mean change from baseline in postprandial (after mealtime) FFA 30 minutes after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.
| mEg/L | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial FFA at Week 12 in the 0-40 mg Cohort | 0.01 ± 0.03 | -0.00 ± 0.03 | -0.06 ± 0.03 | -0.05 ± 0.03 | -0.04 ± 0.03 | -0.00 ± 0.03 |
Adjusted mean change from baseline in postprandial (after mealtime) glucagon excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| pg/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Glucagon Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -5.94 ± 3.64 | -5.75 ± 4.42 | -10.39 ± 3.60 | -3.94 ± 4.02 | -6.99 ± 3.76 | 3.58 ± 3.45 | -8.54 ± 3.87 | 0.52 ± 4.07 |
Adjusted mean change from baseline in postprandial (after mealtime) glucagon excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.
| pg/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial Glucagon Excursion at Week 12 in the 0-40 mg Cohort | -5.96 ± 3.29 | -4.46 ± 4.47 | -6.80 ± 3.42 | -10.36 ± 3.74 | -8.56 ± 3.47 | 4.53 ± 3.17 |
Adjusted mean change from baseline in postprandial (after mealtime) FFA excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts.
| mEq/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial FFA Excursion at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -0.02 ± 0.02 | 0.01 ± 0.02 | -0.02 ± 0.02 | 0.00 ± 0.02 | 0.02 ± 0.02 | -0.01 ± 0.02 | -0.07 ± 0.02 | -0.12 ± 0.03 |
Adjusted mean change from baseline in postprandial (after mealtime) FFA excursion (30 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort.
| mEq/mL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Postprandial FFA Excursion at Week 12 in the 0-40 mg Cohort | -0.01 ± 0.02 | -0.04 ± 0.03 | 0.02 ± 0.02 | -0.01 ± 0.02 | 0.03 ± 0.02 | -0.04 ± 0.02 |
Mean change from baseline in 15-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.
| units on a scale | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Insulinogenic Index at Week 6 in the 0-40 and 0 & 100 mg Cohorts | 0.38 ± 2.04 | -0.31 ± 2.41 | 0.45 ± 1.88 | -0.22 ± 1.22 | 0.04 ± 2.00 | 0.22 ± 1.80 | -0.25 ± 4.52 | -0.63 ± 2.77 |
Mean change from baseline in 15-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.
| units on a scale | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 15-minute Insulinogenic Index at Week 12 in the 0-40 mg Cohort | 0.50 ± 2.03 | -0.19 ± 1.77 | -0.13 ± 1.91 | -0.34 ± 1.21 | 0.22 ± 1.54 | -0.05 ± 1.38 |
Mean change from baseline in 30-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.
| units on a scale | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Insulinogenic Index at Week 6 in the 0-40 and 0 & 100 mg Cohorts. | 0.44 ± 1.06 | 0.37 ± 0.76 | 0.31 ± 0.77 | 0.18 ± 0.81 | 0.71 ± 3.71 | 0.04 ± 0.72 | 0.46 ± 1.17 | -0.05 ± 0.83 |
Mean change from baseline in 30-minute insulinogenic index of a MTT achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The insulinogenic index is a unitless scale which is a measure of insulin production normalized for the glucose stimulus. Higher numbers mean more beta cell function (improvement). The low value is zero. The highest value obtainable is unknown.
| units on a scale | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in 30-minute Insulinogenic Index at Week 12 in the 0-40 mg Cohort | 0.15 ± 0.99 | 0.84 ± 2.31 | 0.35 ± 0.97 | -0.05 ± 0.50 | 0.25 ± 0.58 | 0.11 ± 0.44 |
Mean change from baseline in Matsuda index achieved at each dose of saxagliptin at Week 6 in the 0-40 mg and the 0 \& 100 mg cohorts. The Matsuda index is a scale designed to give numbers between 0 and 12, with a linear relationship to other indices of insulin sensitivity. The higher the number, the better the insulin sensitivity (improvement).
| units on a scale | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Matsuda Index at Week 6 in the 0-40 and 0 & 100 mg Cohorts | -0.36 ± 1.36 | 0.31 ± 1.27 | -0.04 ± 2.84 | 0.31 ± 1.76 | -0.06 ± 2.49 | -0.25 ± 1.91 | 0.86 ± 2.86 | 0.35 ± 2.45 |
Mean change from baseline in Matsuda index achieved at each dose of saxagliptin at Week 12 in the 0-40 mg cohort. The Matsuda index is a scale designed to give numbers between 0 and 12, with a linear relationship to other indices of insulin sensitivity. The higher the number, the better the insulin sensitivity (improvement).
| units on a scale | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| Change From Baseline in Matsuda Index at Week 12 in the 0-40 mg Cohort | -0.48 ± 2.81 | 0.34 ± 1.21 | 0.27 ± 3.90 | 0.78 ± 3.24 | 0.17 ± 3.68 | -0.15 ± 1.66 |
Mean change from baseline in A1C achieved at each dose of saxagliptin during the Follow-Up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 \& 100 mg cohort.
| percentage of glycated hemoglobins | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in A1C at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts | -0.55 ± 0.93 | -0.84 ± 1.04 | -0.78 ± 0.98 | -0.66 ± 1.03 | -0.69 ± 1.04 | -0.25 ± 0.83 | -1.15 ± 0.76 | -0.45 ± 0.65 |
Mean change from baseline in A1C achieved at each dose of saxagliptin during the Follow-Up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 \& 100 mg cohort.
| percentage of glycated hemoglobins | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in A1C at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts | -0.34 ± 0.98 | -0.72 ± 0.96 | -0.64 ± 0.99 | -0.57 ± 0.94 | -0.53 ± 0.97 | -0.24 ± 0.87 | -1.01 ± 0.70 | -0.43 ± 0.80 |
Mean change from baseline in FSG achieved at each dose of saxagliptin during Follow-Up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 \& 100 mg cohort.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in FSG at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts | -1.93 ± 36.86 | -14.03 ± 34.62 | -7.58 ± 29.35 | -11.17 ± 33.97 | -6.02 ± 38.40 | -0.75 ± 29.11 | -14.14 ± 26.14 | -3.47 ± 26.80 |
Mean change from baseline in FSG achieved at each dose of saxagliptin during the follow-up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 \& 100 mg cohort.
| mg/dL | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in FSG at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts | -5.82 ± 31.60 | -11.55 ± 33.73 | -6.65 ± 46.36 | -9.05 ± 28.62 | -0.91 ± 33.94 | -2.04 ± 40.19 | -7.82 ± 23.88 | -5.97 ± 21.76 |
Mean change from baseline in fructosamine achieved at each dose of saxagliptin during the Follow-up period at Week 14 in the 0-40 mg cohort and at Week 8 in the 0 \& 100 mg cohort.
| umol/L | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Fructosamine at 2 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts | -12.40 ± 35.18 | -19.78 ± 33.80 | -12.77 ± 37.92 | -17.10 ± 39.36 | -12.81 ± 32.41 | -7.48 ± 34.15 | -21.86 ± 31.39 | -5.97 ± 23.67 |
Mean change from baseline in fructosamine achieved at each dose of saxagliptin during the Follow-up period at Week 16 in the 0-40 mg cohort and at Week 10 in the 0 \& 100 mg cohort.
| umol/L | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Fructosamine at 4 Weeks After Discontinuation of Double-Blind Study Medication in the 0-40 and 0 & 100 mg Cohorts | -8.60 ± 39.61 | -8.02 ± 37.54 | -11.02 ± 40.73 | -19.44 ± 37.39 | -10.14 ± 31.45 | -7.05 ± 35.13 | -15.25 ± 30.78 | -10.00 ± 24.26 |
Adjusted mean change from baseline in A1C achieved at each dose of saxagliptin at Week 6 in subjects with baseline A1C \<7%, ≥7% to \<8%, ≥8% to \<9%, and ≥9% in the 0 \& 100 mg cohort.
| percent | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|
| <7% (n=8; n=12) | -0.61 ± 0.26 | -0.18 ± 0.27 |
| ≥7% to <8% (n=20; n=8) | -1.01 ± 0.41 | -0.30 ± 0.15 |
| ≥8% to <9% (n=9; n=11) | -1.14 ± 0.53 | -0.34 ± 0.95 |
| ≥9% (n=6; n=4) | -2.10 ± 0.88 | -0.83 ± 0.31 |
Adjusted mean change from baseline in FSG achieved at each dose of saxagliptin at Week 6 in subjects with baseline FSG \<140 mg/dL, ≥140 mg/dL to \<180 mg/dL, and ≥ 180 mg/dL in the 0 \& 100 mg cohort.
| mg/dL | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|
| < 140 mg/dL (n=17; n=17) | -11.12 ± 12.51 | 1.29 ± 12.95 |
| 140 - < 180 mg/dL (n=17; n=14) | -27.00 ± 19.47 | 0.07 ± 26.78 |
| ≥180 mg/dL (n=9; n=6) | -56.89 ± 25.21 | -19.50 ± 48.14 |
Adjusted mean change from baseline in 60-minute postprandial glucose achieved at each dose of saxagliptin at Week 6 in subjects with baseline 60-minute postprandial glucose \<140 mg/dL, ≥140 to \<200 mg/dL, and ≥200 mg/dL in the 0 \& 100 mg cohort.
| mg/dL | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|
| <140 mg/dL (n=1; n=3) | -18.00 ± 0.00 | 11.33 ± 12.10 |
| ≥140 to <200 mg/dL (n=17; n=12) | -24.29 ± 21.44 | -19.25 ± 25.30 |
| ≥200 mg/dL (n=20; n=20) | -62.10 ± 34.83 | -21.35 ± 57.10 |
Percentage of participants achieving A1C \< 7%, the American Diabetic Association's defined goal for glycemia, at each dose of saxagliptin at Week 6 in the 0 \& 100 mg cohort.
| Percentage of Participants | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|
| Percentage of Participants Achieving A1C < 7% at Week 6 in the 0 & 100 mg Cohort | 72 | 49 |
Adjusted mean change from baseline in postprandial FFA excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0 \& 100 mg cohort. (Note: this analysis was not performed.)
No measurements were reported for this outcome.
Adjusted mean change from baseline in postprandial glucagon excursion (60 minutes minus 0 minutes) after a MTT achieved at each dose of saxagliptin at Week 6 in the 0 \& 100 mg cohort. (Note: this analysis was not performed.)
No measurements were reported for this outcome.
Number of participants discontinuing from the double-blind phase due to lack of glycemic control at Week 4 and Week 6. (Note: this analysis was not performed.)
No measurements were reported for this outcome.
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
| Percentage of participants | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| At least one AE | 80.0 | 76.6 | 77.8 | 87.0 | 75.0 | 79.1 |
| At least one SAE | 1.8 | 0 | 1.6 | 1.9 | 0 | 1.5 |
| At least one related AE | 14.5 | 23.4 | 22.2 | 25.9 | 23.1 | 23.9 |
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 |
| Discontinuations due to AEs | 0 | 2.1 | 1.6 | 1.9 | 3.8 | 1.5 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
| Percentage of participants | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 Cohort) |
|---|---|---|
| At least one AE | 65.9 | 58.5 |
| At least one SAE | 0 | 0 |
| At least one related AE | 22.7 | 12.2 |
| Deaths | 0 | 0 |
| Discontinuations due to AEs | 0 | 0 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
| Percentage of participants | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|
| At least one AE | 34.0 | 42.9 | 37.9 | 37.5 | 42.6 | 26.7 |
| At least one SAE | 0 | 0 | 0 | 2.1 | 0 | 1.7 |
| At least one related AE | 4.0 | 7.1 | 3.4 | 12.5 | 4.3 | 6.7 |
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 |
| Discontinuations due to AEs | 0 | 0 | 0 | 0 | 0 | 0 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
| Percentage of participants | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) |
|---|---|---|
| At least one AE | 31.8 | 33.3 |
| At least one SAE | 0 | 0 |
| At least one related SAE | 2.3 | 0 |
| Deaths | 0 | 0 |
| Discontinuations due to AEs | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saxagliptin 10 mg (0-40 mg Cohort) | — | 1/63 (1.6%) | 36/63 (57.1%) |
| Saxagliptin 100 mg (0 & 100 mg Cohort) | — | 0/44 (0%) | 16/44 (36.4%) |
| Saxagliptin 2.5 mg (0-40 mg Cohort) | — | 1/55 (1.8%) | 35/55 (63.6%) |
| Saxagliptin 20 mg (0-40 mg Cohort) | — | 2/54 (3.7%) | 33/54 (61.1%) |
| Saxagliptin 40 mg (0-40 mg Cohort) | — | 0/52 (0%) | 27/52 (51.9%) |
| Saxagliptin 5 mg (0-40 mg Cohort) | — | 0/47 (0%) | 23/47 (48.9%) |
| Placebo (0 & 100 mg Cohort) | — | 0/41 (0%) | 17/41 (41.5%) |
| Placebo (0-40 mg Cohort) | — | 2/67 (3%) | 38/67 (56.7%) |
| Event | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Placebo (0 & 100 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| RectoceleGastrointestinal disorders | 0/63 | 0/44 | 0/55 | 1/54 | 0/52 | 0/47 | 0/41 | 0/67 |
| GastroenteritisInfections and infestations | 0/63 | 0/44 | 0/55 | 1/54 | 0/52 | 0/47 | 0/41 | 0/67 |
| CystoceleRenal and urinary disorders | 0/63 | 0/44 | 0/55 | 1/54 | 0/52 | 0/47 | 0/41 | 0/67 |
| PneumoniaInfections and infestations | 0/63 | 0/44 | 1/55 | 0/54 | 0/52 | 0/47 | 0/41 | 0/67 |
| AppendicitisInfections and infestations | 1/63 | 0/44 | 0/55 | 0/54 | 0/52 | 0/47 | 0/41 | 0/67 |
| Umbilical HerniaGastrointestinal disorders | 0/63 | 0/44 | 0/55 | 0/54 | 0/52 | 0/47 | 0/41 | 1/67 |
| Urinary Tract InfectionInfections and infestations | 0/63 | 0/44 | 0/55 | 0/54 | 0/52 | 0/47 | 0/41 | 1/67 |
| Event | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Placebo (0 & 100 mg Cohort) | Placebo (0-40 mg Cohort) |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 10/63 | 5/44 | 8/55 | 6/54 | 5/52 | 4/47 | 2/41 | 6/67 |
| Oedema PeripheralGeneral disorders | 4/63 | 2/44 | 0/55 | 1/54 | 2/52 | 1/47 | 1/41 | 8/67 |
| NasopharyngitisInfections and infestations | 5/63 | 1/44 | 0/55 | 3/54 | 6/52 | 2/47 | 1/41 | 5/67 |
| Upper Respiratory Tract InfectionInfections and infestations | 6/63 | 0/44 | 6/55 | 6/54 | 0/52 | 3/47 | 0/41 | 4/67 |
| Urinary Tract InfectionInfections and infestations | 4/63 | 4/44 | 6/55 | 5/54 | 2/52 | 2/47 | 2/41 | 5/67 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/63 | 1/44 | 6/55 | 5/54 | 2/52 | 3/47 | 1/41 | 2/67 |
| NauseaGastrointestinal disorders | 2/63 | 0/44 | 1/55 | 2/54 | 5/52 | 2/47 | 2/41 | 5/67 |
| DyspepsiaGastrointestinal disorders | 1/63 | 0/44 | 0/55 | 4/54 | 1/52 | 1/47 | 0/41 | 0/67 |
| Back PainMusculoskeletal and connective tissue disorders | 1/63 | 0/44 | 3/55 | 4/54 | 1/52 | 2/47 | 0/41 | 3/67 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/63 | 2/44 | 4/55 | 3/54 | 3/52 | 3/47 | 0/41 | 3/67 |
| Age, Customized(participants) | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) | Total |
|---|---|---|---|---|---|---|---|---|---|
| <65 years | 50 | 39 | 54 | 50 | 41 | 55 | 38 | 35 | 362 |
| >= 65 years | 5 | 8 | 9 | 4 | 11 | 12 | 6 | 6 | 61 |
| Sex: Female, Male(Participants) | Saxagliptin 2.5 mg (0-40 mg Cohort) | Saxagliptin 5 mg (0-40 mg Cohort) | Saxagliptin 10 mg (0-40 mg Cohort) | Saxagliptin 20 mg (0-40 mg Cohort) | Saxagliptin 40 mg (0-40 mg Cohort) | Placebo (0-40 mg Cohort) | Saxagliptin 100 mg (0 & 100 mg Cohort) | Placebo (0 & 100 mg Cohort) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 33 | 22 | 23 | 16 | 22 | 25 | 17 | 18 | 176 |
| Male | 22 | 25 | 40 | 38 | 30 | 42 | 27 | 23 | 247 |
No study locations are listed for this record.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca